Last reviewed · How we verify

Lisata Therapeutics, Inc. — Portfolio Competitive Intelligence Brief

Lisata Therapeutics, Inc. pipeline: 0 marketed, 0 filed, 1 Phase 3, 4 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 1 Phase 3 4 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Auto-CD34+ cells Auto-CD34+ cells phase 3 Cell therapy Regenerative Medicine / Cardiovascular

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Biosolution Co., Ltd. · 1 shared drug class
  2. Bone Therapeutics S.A · 1 shared drug class
  3. Brainstorm-Cell Therapeutics · 1 shared drug class
  4. Celavie Bioscences, LLC · 1 shared drug class
  5. China Spinal Cord Injury Network · 1 shared drug class
  6. City of Hope Medical Center · 1 shared drug class
  7. Diakonos Oncology Corporation · 1 shared drug class
  8. Avicenna Research Institute · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Lisata Therapeutics, Inc.:

Cite this brief

Drug Landscape (2026). Lisata Therapeutics, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/lisata-therapeutics-inc. Accessed 2026-05-16.

Related